AbbVie Launches Allergan Aesthetics Learning Platform
The educational platform is targeted at HCPs and their staff.
Stock.adobe.com
AbbVie launched a new learning platform designed to provide hcps, staff, and management about the company’s Allergan Aesthetics brand and products.1 The platform is available for free for all Allergan Aesthetics customers and is part of AbbVie’s investment in its AMI platform.
In a press release, U.S. Allergan Aesthetics senior vice president Glen Curran said, “Allergan Aesthetics designed AMI Business to meet providers where they are—supporting them with practical, business-focused education related to our products to complement their clinical expertise and help them grow their practices and deliver on patient needs. We are excited to provide these courses free of charge through AMI Online, giving all of our customers access to valuable resources that help them thrive in this dynamic industry."
Allergan Aesthetics develops, manufactures, and markets a portfolio of aesthetics brands and products, including facial injectables, body contouring, plastics, and skin care. The new learning platform will include educational material about the brand’s products, along with broader business-centered modules. This includes lessons on goals setting and creating lifetime patient partnerships.
In the same press release, board-certified plastic surgeon Dr. Joseph A. Russo said, “As a clinician and an educator in the aesthetic space, one of the biggest challenges we face is running and growing a business while improving our clinical skills to provide great outcomes for our patients. The AMI Business modules offer valuable insights for growing practices."
AbbVie also recently announced the winners of its first Migraine Career Catalyst Award, which is focused on telling the stories of migraine-sufferers navigating their careers while also managing their condition.2
In a press release issued at the time, AbbVie senior vice president and president of neuroscience and eye care Jag Dosanjh said, “Migraine can significantly affect an individual's career trajectory and long-term potential. Despite these challenges, the recipients of the inaugural AbbVie Migraine Career Catalyst Award have shared their remarkable determination to overcome disease-related obstacles as they work toward their professional aspirations. As the only company with three treatment options that collectively address the entire spectrum of migraine, we have a deep understanding of the challenges that people living with migraine can face in the workplace, and we're proud to support these individuals as they lead lives that transcend obstacles often imposed by the impact of the disease."
Melissa, a migraine-sufferer from Davis, West Virginia, is one of the winners of this year’s contest. In the same press release, she discussed her experience, saying, “Migraine impacted my life in ways that I hadn't anticipated. I spent most of my career working in state parks, outdoor recreation, and tourism. However, the demands of public service combined with the unpredictability of migraine have made life incredibly challenging. This award will allow me to create a mentorship program in my small town and share my experience and knowledge in outdoor recreation with the next generation, ensuring that they are better equipped to navigate the challenges of their careers with or without migraine."
Sources
- Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products. AbbVie. November 18, 2024. Accessed November 21, 2024. https://news.abbvie.com/2024-11-18-Allergan-Aesthetics-Offers-Free-Business-Education-Courses-Online-to-Support-Growing-Practices-with-Allergan-Aesthetics-Products
- AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations. AbbVie. November 14, 2024. Accessed November 21, 2024. https://news.abbvie.com/2024-11-14-AbbVie-Awards-20-Individuals-Living-With-Migraine-To-Support-Career-Aspirations
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
